Cargando…
Randomized phase III trial of radiotherapy or chemoradiotherapy with topotecan and cisplatin in intermediate-risk cervical cancer patients after radical hysterectomy
BACKGROUND: In cervical cancer patients with intermediate-risk factors, the optimal adjuvant therapy is still controversial. We undertook a randomized trial (ClinicalTrials.gov Identifier: NCT01418859) to compare the efficacy and toxicity of concurrent chemoradiotherapy with topotecan and cisplatin...
Autores principales: | Sun, Wenze, Wang, Tao, Shi, Fan, Wang, Jiquan, Wang, Juan, Hui, Beina, Zhang, Yingbing, Lu, Jinli, Chen, Hongwei, Liu, Zi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425857/ https://www.ncbi.nlm.nih.gov/pubmed/25935645 http://dx.doi.org/10.1186/s12885-015-1355-1 |
Ejemplares similares
-
Association Between Bone Marrow Dosimetric Parameters and Acute Hematologic Toxicity in Cervical Cancer Patients Undergoing Concurrent Chemoradiotherapy: Comparison of Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiation Therapy
por: Hui, Beina, et al.
Publicado: (2014) -
Cost-effectiveness of radical hysterectomy with adjuvant radiotherapy versus radical radiotherapy for FIGO stage IIB cervical cancer
por: Chai, Yanlan, et al.
Publicado: (2016) -
Pristimerin enhances the effect of cisplatin by inhibiting the miR-23a/Akt/GSK3β signaling pathway and suppressing autophagy in lung cancer cells
por: Zhang, Yingbing, et al.
Publicado: (2019) -
Radical hysterectomy with adjuvant radiotherapy versus radical radiotherapy for FIGO stage IIB cervical cancer
por: Chai, Yanlan, et al.
Publicado: (2014) -
Chemoradiotherapy is not superior to radiotherapy alone after radical surgery for cervical cancer patients with intermediate-risk factor
por: Kim, Hakyoung, et al.
Publicado: (2019)